Recently, HER2-targeted cancer immunotherapy using recombinant Listeria monocytogenes, which expresses a chimeric human HER2/neu construct, was shown to prolong the overall survival and reduce metastasis rates in canine models of pediatric osteosarcomas [43]. Here, ERBB2 is linked to osteosarcoma.